Evidence map›Paper›PMID 30689993›Full record

ArticleEuropean journal of pharmacology2019

Ligand-directed serotonin 5-HT

Daniel E Felsing, Clinton E Canal, Raymond G Booth

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. An Update on the Implications of New Psychoactive Substances in Public Health.International journal of environmental research and public health · 2022
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniel E FelsingCenter for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States; Department of Medicinal Chemistry, University of Florida, Gainesville, FL 32610, United States. Electronic address: defelsin@utmb.edu.
Clinton E CanalCenter for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States. Electronic address: canal_ce@mercer.edu.
Raymond G BoothCenter for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115, United States; Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, United States; Department of Medicinal Chemistry, University of Florida, Gainesville, FL 32610, United States. Electronic address: ra.booth@neu.edu.

Funding

Serotonin 5HT2C Agonist Drugs with 5HT2A/2B Antagonist ActivityR01MH081193 · NIMH · UNIVERSITY OF FLORIDA · PI BOOTH, RAYMOND G. · 2008 to 2012
$1.8M
Novel Functionally-Selective Serotonin 5HT2 Drugs for Amphetamines Abuse/DisorderR01DA030989 · NIDA · UNIVERSITY OF FLORIDA · PI BOOTH, RAYMOND G., MORGAN, DRAKE · 2010 to 2014
$1.6M
Receptor pharmacology and toxicology of second-generation pyrrolidine "bath salt" cathinonesR21DA040907 · NIDA · NORTHEASTERN UNIVERSITY · PI CANAL, CLINTON E, MURNANE, KEVIN SEAN · 2016 to 2017
$493k
NIDA NIH HHS R01 DA030989NIDA NIH HHS R21 DA040907NIMH NIH HHS R01 MH081193
6 · The paper itself

Abstract

Exposure of G protein-coupled receptors (GPCRs) to agonists can desensitize receptor signaling and lead to drug tolerance, whereas inverse agonists can sensitize signaling. For example, activation of serotonin 5-HT

Indexed as

AnimalsCHO CellsCricetinaeCricetulusHumansLigandsReceptor, Serotonin, 5-HT2CSerotonin 5-HT3 Receptor AgonistsLigandsReceptor, Serotonin, 5-HT2CSerotonin 5-HT3 Receptor Agonists5-HT(2C) receptorAminotetralinDesensitizationphospholipase CSensitizationβ-arrestin

Identifiers

PMID30689993
PMCPMC6767919

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.